Treatment of Exudative Age-related Macular Degeneration: Many Factors to Consider
- 31 August 2007
- journal article
- editorial
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 144 (2), 281-283
- https://doi.org/10.1016/j.ajo.2007.05.005
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Retinal Pigment Epithelial Tear After Intravitreal Bevacizumab InjectionAmerican Journal of Ophthalmology, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTSRetina, 2006
- SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal AdministrationInvestigative Opthalmology & Visual Science, 2005